Program
fostemsavir
Also written as “BMS-663068”, “Fostemsavir 600 mg” and “Fostemsavir 200 mg”.
Its studies are mostly in Infections · HIV Infections, led by GlaxoSmithKline.
Drug pageFostemsavir: every studyAll 22 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 192 open or running | phase 3since Feb 9, 2015 | Nov 6, 2009 | Sep 14, 2032phase 3 · NCT07393659 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Nov 6, 2009.
- May 13, 2014Phase 1 study in InfectionsNCT02138084 · 102 enrolled · United States
- Jun 12, 2014Phase 1 study in InfectionsNCT02164045 · 38 enrolled · United States
- Sep 5, 2014Phase 1 study in HIV InfectionsNCT02234882 · 50 enrolled
- Oct 27, 2014Phase 1 study in InfectionsNCT02277600 · 32 enrolled · United States
- Feb 9, 2015Phase 3 study in HIV InfectionsNCT02362503 · 371 enrolled · United States, Argentina, Australia and more
- May 20, 2015Phase 1 study in InfectionsNCT02467335 · 52 enrolled · United States
- Jun 16, 20152 phase 1 studies in InfectionsNCT02480894, NCT02480881
- Jul 22, 2015Phase 1 study in InfectionsNCT02508064 · 27 enrolled · United Kingdom
- Dec 21, 2015Phase 1 study in HIV InfectionsNCT02674581 · 30 enrolled · United States
- Jan 6, 20162 phase 1 studies in InfectionsNCT02666001, NCT02666053
- May 31, 2016Phase 1 study in InfectionsNCT02805556 · 36 enrolled · United Kingdom
- Jun 9, 2016Named fostemsavirINNProposed as its International Nonproprietary Name in WHO's List 115 · before, BMS-663068
- Jul 28, 2016Phase 1 study in InfectionsNCT02859259 · 14 enrolled · United States
- Feb 12, 2021Phase 1 study in HIV InfectionsNCT04757974 · 48 enrolled · United States
- Jan 30, 2026Phase 3 study in HIV InfectionsNCT07393659 · 197 planned · Romania, South Africa, Uganda
Ahead
- Sep 14, 2032Primary completion: phase 3 study in HIV InfectionsNCT07393659
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Envelope polyprotein GP160 inhibitor; Envelope polyprotein GP160 inhibitor”ChEMBL 37, by rule
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07393659HIV Infections · Romania, South Africa, Uganda | 3 | Recruiting | Sep 14, 2032 | 197 |
| NCT04757974HIV Infections · United States | 1 | Completed | Jul 31, 2021 | 48 |
| NCT02859259Infections · United States | 1 | Completed | Aug 12, 2016 | 14 |
| NCT02805556Infections · United Kingdom | 1 | Completed | May 5, 2016 | 36 |
| NCT02666053Infections · United States | 1 | Completed | Feb 22, 2016 | 72 |
| NCT02666001Infections · United States | 1 | Completed | Jun 29, 2016 | 32 |
| NCT02674581HIV Infections · United States | 1 | Completed | May 24, 2016 | 30 |
| NCT02508064Infections · United Kingdom | 1 | Completed | Nov 5, 2015 | 27 |
| NCT02480881Infections · United States | 1 | Completed | Jan 11, 2016 | 26 |
| NCT02480894Infections · United States | 1 | Completed | Sep 21, 2015 | 112 |
| NCT02467335Infections · United States | 1 | Completed | Oct 3, 2015 | 52 |
| NCT02362503HIV Infections · United States, Argentina, Australia and more | 3 | Active, not recruiting | Aug 18, 2016 | 371 |
| NCT02277600Infections · United States | 1 | Completed | Jan 12, 2015 | 32 |
| NCT02234882HIV Infections | 1 | Completed | Oct 31, 2014 | 50 |
| NCT02164045Infections · United States | 1 | Completed | Jul 25, 2014 | 38 |
| NCT02138084Infections · United States | 1 | Completed | Jul 24, 2014 | 102 |
| NCT02063360Infections | 1 | Completed | May 1, 2014 | 42 |
| NCT01384734Infections · United States, Argentina, Colombia and more | 2 | Completed | Feb 18, 2013 | 254 |
| NCT01009814HIV Infections · Germany | 2 | Completed | Jun 25, 2010 | 50 |
How it is read
Names in the registry
- “BMS-663068”, 14 entries
- “Fostemsavir 600 mg”, 1 entry
- “Fostemsavir 200 mg”, 1 entry
- “Fostemsavir”, 1 entry
- “BMS-663068 400 mg”, 1 entry
Conditions, from the studies’ own filings
- Infections, 13 studies
- HIV Infections, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.